-
Levofloxacin: Workflows for Bacterial and Bone Assays
2026-08-22
Levofloxacin supports two distinct research lanes: bacterial DNA replication studies and carefully controlled models of osteoblast and cartilage biology. This workflow-focused guide translates mechanism, exposure design, and assay controls into practical experiments while separating established product findings from exploratory recommendations.
-
Temafloxacin MIC Design: From Assay to Insight
2026-08-21
Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent whose value in research depends on more than a single MIC result. This guide connects Gram-positive susceptibility data, intracellular testing, formulation controls, and translational model selection into a practical assay strategy.
-
UBR1 and UBR2 in Mammalian ER Stress Sensing
2026-08-20
The reference study identifies the N-recognins UBR1 and UBR2 as stress-responsive E3 ubiquitin ligases that help protect mammalian cells from ER stress-induced apoptosis. Its findings expand the known ER-associated degradation network by connecting the N-degron pathway to global protein quality control and provide a framework for interpreting stress, ubiquitination, and cell-survival experiments.
-
Haloprogin: Findings from a Foundational 1970 Study
2026-08-20
The reference study established Haloprogin as a topical antifungal agent whose dermatophyte activity was comparable to tolnaftate while adding notable activity against Candida species and selected Gram-positive bacteria. Its combination of serial-dilution testing, fungicidal confirmation, formulation screening, and guinea pig infection experiments provides a useful historical framework for dermatophytosis and Candida-focused antimicrobial research.
-
Shufeng Xingbi Therapy in Allergic Rhinitis Rats
2026-08-19
This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in ovalbumin-induced rats by integrating nasal inflammation, Th1/Th2-associated signaling, serum mediators, short-chain fatty acids, and intestinal microbiota. Its main contribution is a multi-level model linking symptom improvement with gut microbial and immune changes, while its preclinical design and incomplete mechanistic resolution limit direct clinical translation.
-
Metronidazole in Reliable Cell Assays
2026-08-19
Learn how Metronidazole, SKU B1976, can help laboratories distinguish transporter-mediated effects from true cytotoxicity in cell-based assays. This scenario-driven guide covers concentration design, solvent compatibility, storage, interpretation, and practical supplier selection using documented chemical and pharmacological data.
-
Temafloxacin: From MICs to Mechanism-Aware Assays
2026-08-18
Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent whose value depends on matching mechanism, pathogen, and assay context. This guide connects MIC interpretation and intracellular testing with a bioprocess-design study to show how experimental structure improves reproducibility without overextending the evidence.
-
Haloprogin: Antifungal Evidence & Research Use
2026-08-18
Haloprogin is a topical antimicrobial compound with documented in vitro activity against dermatophytes, Candida albicans, and selected Gram-positive bacteria. Its strongest evidence comes from historical susceptibility testing and guinea pig dermatophytosis models, while its precise molecular targets remain unresolved.
-
IDH2, α-KG, and HIF-1α in Colorectal Cancer
2026-08-17
A 2024 study identifies elevated IDH2 as a metabolic driver of colorectal cancer progression, linking reductive TCA-cycle activity to α-ketoglutarate availability, ATP production, glycolysis, and HIF-1α signaling. Its combined genetic, pharmacological, metabolic, and in vivo evidence suggests that IDH2-dependent carbon flux may represent a testable vulnerability in CRC models.
-
Dimetridazole Disarms P. aeruginosa Virulence
2026-08-17
Yuan et al. showed that Dimetridazole and Ribavirin can reduce Pseudomonas aeruginosa virulence by suppressing quorum sensing rather than relying primarily on bacterial killing. The study combines phenotypic assays, transcriptomics, antibiotic-combination testing, and Caenorhabditis elegans and mouse infection models to support an antivirulence research strategy.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-08-16
Build sensitive immunofluorescence, flow cytometry, and fluorescent tissue-staining workflows around a reliable fluorescein-conjugated secondary antibody. This guide connects practical assay design with the IL-11/GP130 pulmonary-fibrosis research landscape while emphasizing controls, storage, and troubleshooting.
-
PPARγ Activation Rebalances Macrophages in DSS Colitis
2026-08-15
This study identifies PPARγ activation as a regulator of M1/M2 macrophage polarization in dextran sulfate sodium-induced inflammatory bowel disease. Using RAW264.7 cells and a mouse colitis model, the authors connect reduced STAT-1 phosphorylation and enhanced STAT-6 phosphorylation with improved intestinal barrier integrity and clinical disease features.
-
N1-Methyl-Pseudouridine-5'-Triphosphate Workflow
2026-08-14
Build more stable, translation-ready RNA with N1-Methyl-Pseudouridine-5'-Triphosphate while preserving a clear path from in vitro transcription to cell-based testing. The workflow also shows how junction-resolved assays inspired by R2 retrotransposon research can separate RNA quality effects from downstream DNA-repair outcomes.
-
Plk1 Control of Mitotic Checkpoint Disassembly
2026-08-14
The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-dependent mitotic checkpoint complex disassembly. Its evidence shows that Plk1 phosphorylates p31comet at S102, suppressing cooperation with TRIP13 and helping prevent premature cycling between checkpoint assembly and disassembly.
-
Polymyxin B Sulfate Workflows for Infection Research
2026-08-13
Build reproducible Gram-negative infection, LPS-perturbation, and dendritic-cell experiments with Polymyxin B sulfate. This guide separates membrane-disruptive antimicrobial effects from immune-signaling artifacts while translating recent microbiome–immunotherapy findings into practical assay controls.